There is reason for the enthusiasm behind Elevation’s anti-Claudin18.2 ADC, but no such good news for Zai Lab’s zolbetuximab challenger.
One of the most momentous Asco abstracts drops of recent years sends Verastem up 126%.
Despite the often dismal mood over the weekend, the Asco conference provided rich pickings for some biotech investors.
Response rates with zenocutuzumab hold up, but Elevation Oncology’s rival project looks similar.
Unveiled abstracts from Asco lift the stock of several biotechs, which will now be under pressure not to disappoint at the conference next week.
The group still has its eye on accelerated approval, though genetic testing casts a long shadow.